Clinical Trial Update: A Study to Investigate the Tolerability of Subcutaneous (SC) Trastuzumab Administration in Participants With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Early Breast Cancer (eBC) Using Either a Single-Use Injection Device or Manual Administration [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluated tolerability of subcutaneous trastuzumab administration in HER2-positive early breast cancer using a single-use injection dev…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Trastuzumab (trastuzumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Breast Cancer | Phase 3 | Status: COMPLETED